World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites.
The World Health Organization (WHO) estimates that >2 million people will have started antiretroviral therapy (ART) by the end of 2006. As the development of some HIV drug resistance (HIVDR) is inevitable in populations taking ART, the emergence of HIVDR must be balanced against the benefits of providing ART, including improved health outcomes and decreased HIV/AIDS-associated morbidity and mortality. ART programmes should operate to minimize the emergence of HIVDR in populations receiving therapy and HIVDR itself must be monitored to ensure ongoing regimen efficacy. ART regimens in resource-limited settings are usually selected at the national level following a public health approach: generally only one first-line regimen with alternate regimen(s) incorporating within-class drug substitutions are available in the public sector. The WHO has developed a population-based HIVDR assessment and prevention strategy, which includes standardized HIVDR monitoring surveys in populations receiving first-line ART at sentinel sites. The WHO surveys monitor HIVDR prevention in sentinel sites by utilizing a standardized, minimum-resource prospective survey methodology to assess the success of adult and paediatric ART sites in preventing HIVDR emergence during the first year of ART. The surveys also identify associated factors that can be addressed at the level of the ART site or programme. WHO HIVDR monitoring surveys are designed to be integrated easily into a country's ongoing, routine HIV-related evaluation activities. Performed regularly at representative sites, the data generated will inform evidence-based decision making regarding national and global ART regimen selection and minimize the emergence of HIVDR at a population level.
Tufts University School of Medicine, Boston, MA, USA. mjordan@tuftsmedicalcenter.org
Michael R
MR
Jordan
Diane E
DE
Bennett
Silvia
S
Bertagnolio
Charles F
CF
Gilks
Donald
D
Sutherland
D000328:Adult; D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D003906:Developing Countries; D024882:Drug Resistance, Viral / Q000235:genetics; D019317:Evidence-Based Medicine; D005838:Genotype; D006678:HIV / Q000235:genetics; D015658:HIV Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000635:transmission / Q000821:virology; D019538:Health Care Surveys; D006291:Health Policy; D006801:Humans; D009313:National Health Programs; D017410:Practice Guidelines as Topic; D016730:Program Development; D015397:Program Evaluation; D011446:Prospective Studies; D018571:Sentinel Surveillance; D016896:Treatment Outcome; D019562:Viral Load; D014944:World Health Organization
D044966:Anti-Retroviral Agents